Read by QxMD icon Read

hyperplasia of prostate

Hirokazu Urushiyama, Yasuhiro Terasaki, Shinya Nagasaka, Nariaki Kokuho, Youko Endo, Mika Terasaki, Shinobu Kunugi, Kosuke Makita, Hideaki Isago, Keisuke Hosoki, Kunihiko Souma, Takashi Ishii, Hirotaka Matsuzaki, Yoshihisa Hiraishi, Yu Mikami, Satoshi Noguchi, Hiroyuki Tamiya, Akihisa Mitani, Yasuhiro Yamauchi, Akira Shimizu, Takahide Nagase
Naftopidil, an α-1 adrenoceptor antagonist with few adverse effects, is prescribed for prostate hyperplasia. Naftopidil inhibits prostate fibroblast proliferation; however, its effects on lung fibroblasts and fibrosis remain largely unknown. Two normal and one idiopathic pulmonary fibrosis human lung fibroblast lines were cultured with various naftopidil concentrations with or without phenoxybenzamine, an irreversible α-1 adrenoceptor inhibitor. We examined the incorporation of 5-bromo-2'-deoxyuridine into DNA and lactic acid dehydrogenase release by enzyme-linked immunosorbent assay, cell cycle analysis by flow cytometry, scratch wound-healing assay, and mRNA expressions of type IV collagen and α-smooth muscle actin by polymerase chain reaction...
March 15, 2019: Journal of Cellular and Molecular Medicine
Ling Hao, Yatao Shi, Samuel Thomas, Chad M Vezina, Sagar Bajpai, Arya Ashok, Charles J Bieberich, William A Ricke, Lingjun Li
Dysfunction of the lower urinary tract commonly afflicts the middle-aged and aging male population. The etiology of lower urinary tract symptoms (LUTS) is multifactorial. Benign prostate hyperplasia, fibrosis, smooth muscle contractility, and inflammation likely contribute. Here we aim to characterize the urinary metabolomic profile associated with prostatic inflammation, which could inform future personalized diagnosis or treatment, as well as mechanistic research. Quantitative urinary metabolomics was conducted to examine molecular changes following induction of inflammation via conditional Interleukin-1β expression in prostate epithelia using a novel transgenic mouse strain...
November 2018: International Journal of Mass Spectrometry
Luca Boeri, Paolo Capogrosso, Eugenio Ventimiglia, Matteo Fontana, Gianluca Sampogna, Stefano Paolo Zanetti, Edoardo Pozzi, Rani Zuabi, Nicolò Schifano, Francesco Chierigo, Fabrizio Longo, Franco Gadda, Paolo Guido Dell'Orto, Vincenzo Scattoni, Francesco Montorsi, Emanuele Montanari, Andrea Salonia
BACKGROUND: A significant number of patients who require surgery for benign prostatic hyperplasia are under either anticoagulation (AC) or antiplatelet (AP) therapy. OBJECTIVE: To assess the efficacy and morbidity of holmium laser enucleation of the prostate (HoLEP) and bipolar transurethral enucleation of the prostate (B-TUEP) in patients who required AC/AP therapy. DESIGN, SETTING, AND PARTICIPANTS: This study included 296 (67.6%) and 142 (32...
March 11, 2019: European Urology Focus
Zhongbao Zhou, Yuanshan Cui, Jitao Wu, Rui Ding, Tong Cai, Zhenli Gao
BACKGROUND: We performed a meta-analysis to confirm the efficacy and safety of the combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia (BPH) during a treatment cycle of at least 1 year. METHODS: Randomized controlled trials were searched by using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. Systematic review was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-analyses...
March 11, 2019: BMC Urology
Shiping Wei, Fan Cheng, Weiming Yu
OBJECTIVE: To investigate the safety and efficacy of the combination of suprapubic prostatectomy with transurethral resection of the prostate (TURP) for the treatment of large volume benign prostatic hyperplasia (BPH). METHODS: We retrospectively analyzed the clinical data of two methods of treatment with 60 cases of a large volume BPH (>100 g) from January 2011 to 2017; the methods were suprapubic prostatectomy and suprapubic prostatectomy combination with TURP, in which the single open group comprised 30 cases, treated using the former method, and the combined open group comprised the other 30 cases, treated using the latter method...
March 14, 2019: Urologia
Xiang-Zheng Ma, Kun Lv, Jian-Liang Sheng, Ying-Xing Yu, Pei-Pei Pang, Mao-Sheng Xu, Shi-Wei Wang
The present study aimed to investigate the value of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) combined with quantitative analysis of diffusion weighted imaging (DWI) for the diagnosis of prostate cancer (PCa). A total of 81 patients with prostatic diseases, including PCa (n=44) and benign prostatic hyperplasia (BPH, n=37), were imaged with T1 weighted imaging (T1WI), T2 weighted imaging (T2WI), DWI and DCE-MRI. The blood vessel permeability parameters volume transfer rate constant (Ktrans ), back flow rate constant (Kep ), extravascular extracellular space volume fraction (Ve ), plasma volume fraction (Vp ) and apparent diffusion coefficient (ADC) were measured, and compared between the two groups...
March 2019: Oncology Letters
Katarzyna Grzesiak, Aleksandra Rył, Weronika Ratajczak, Ewa Stachowska, Iwona Rotter, Marcin Słojewski, Olimpia Sipak, Kinga Walczakiewicz, Maria Laszczyńska
The purpose of our investigation was to analyze the relationship between the serum levels of fatty acids and their metabolites and the levels of the selected metabolic and hormonal parameters in patients with benign prostatic hyperplasia (BPH) with regard to concomitant metabolic syndrome (MetS). We determined serum concentrations of total (TT) and free testosterone (FT), insulin (I), dehydroepiandrosterone sulphate (DHEAS), luteinizing hormone and insulin-like growth factor 1 (IGF-1) and sex hormone-binding globulin (SHBG)...
March 13, 2019: Aging
Steven A Kaplan
No abstract text is available yet for this article.
March 13, 2019: Journal of Urology
Wei Sun, Luo Li, Zhongbo Du, Zhen Quan, Mengjuan Yuan, Honglin Cheng, Yingying Gao, Chunli Luo, Xiaohou Wu
Castration‑resistant prostate cancer (CRPC) is a major challenge in the treatment of prostate cancer (PCa). Phospholipase Cε (PLCε), an oncogene, has been found to be involved in the carcinogenesis, tumor proliferation and migration of several types of cancer. The effects, however, of PLCε on CRPC remains unclear. In the present study, the expression of PLCε and glioma‑associated homolog (Gli)‑1/Gli‑2 in benign prostatic hyperplasia (BPH), PCa and CRPC tissues and cells was investigated, and the correlations between PLCε and Gli‑1/Gli‑2 in CRPC tissues and cell lines were further explored...
March 7, 2019: Oncology Reports
Abdullah Erdogan, Salih Polat, Ercument Keskin, Abdullah Turan
OBJECTIVE: Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are the most common benign and malignant diseases of the prostate gland. The clinical distinction between BPH and PCa should be determined to guide patients to appropriate treatment. We aimed to evaluate the value of PSA, prostate volume (PV) and associated parameters for the detection of PCa in patients with PSA levels of 2.5-30.0 ng/mL. MATERIALS AND METHODS: A total of 211 men with a biopsy (≥10 cores) and a PSA of 2...
March 12, 2019: Aging Male: the Official Journal of the International Society for the Study of the Aging Male
Y C Hao, C L Xiao, J Lu, K Liu, Y Q Liu, L L Ma
Objective: To investigate application value of "point-line-surface-volume" four dimensional holmium laser enucleation of prostate (HoLEP) in the treatment of benign prostatic hyperplasia (BPH). Methods: From December 2016 to November 2017, the clinical data of 60 cases of BPH with the treatment of "Point-line-surface-volume" four dimensional HoLEP at Department of Urology, Peking University Third Hospital were analyzed retrospectively. The age was (73.8±8.0) years (range: 60 to 96 years), body mass index was (23...
March 1, 2019: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
Hippocrates Moschouris, Konstantinos Stamatiou, Katerina Malagari, Kyriaki Marmaridou, Konstantinos Kladis-Kalentzis, Michail Kiltenis, Nikolaos Papadogeorgopoulos, Aikaterini Tsavari, Kassiani Manoloudaki
PURPOSE: We aimed to assess the clinical and predictive role of contrast-enhanced ultrasonography (CEUS) as the primary method for imaging evaluation of prostatic artery embolization (PAE) for the treatment of symptomatic benign prostatic hyperplasia (BPH). METHODS: Thirty-one patients with symptomatic BPH, treated with PAE from October 2016 until February 2018, were enrolled in this prospective, single-center study. Microspheres (100-700 µm) were utilized for PAE...
March 2019: Diagnostic and Interventional Radiology: Official Journal of the Turkish Society of Radiology
Jin-Won Noh, Jae-Hyun Kim, Young Dae Kwon, Jae Heon Kim
BACKGROUND: Real treatment rate among patients diagnosed with benign prostatic hyperplasia (BPH/LUTS) and also its association with sociodemographic factor (SDF) have not been extensively investigated. METHODS: Data were obtained from the 2006, 2008, 2010, 2012, 2014, and 2016 waves of the Korean Longitudinal Study of Aging (KLoSA). Among 10,254 individuals at the first baseline survey in 2006, a total of 4383 participants were ultimately included for final analysis...
March 11, 2019: Aging Male: the Official Journal of the International Society for the Study of the Aging Male
Kazuyuki Sakamoto, Yukiko Noguchi, Koji Ueshima, Akiyoshi Ohtake, Shuichi Sato, Katsunori Imazumi, Masahiro Takeda, Noriyuki Masuda
Bladder dysfunctions associated with benign prostatic hyperplasia are not sufficiently alleviated by current pharmacotherapies. Lysophosphatidic acid (LPA) is a phospholipid with diverse biological effects. LPA modulates prostate and urethral contraction via the type 1 LPA (LPA1 ) receptor, suggesting the potential of the LPA1 receptor as a therapeutic target. However, the role of LPA and the LPA1 receptor in bladder function has not been studied in vivo. We investigated the effects of LPA and the novel LPA1 receptor antagonist ASP6432 (potassium 1-(2-{[3,5-dimethoxy-4-methyl-N-(3-phenylpropyl)benzamido]methyl}-1,3-thiazole-4-carbonyl)-3-ethyl-2,2-dioxo-2λ6 -diazathian-1-ide) on the micturition reflex in conscious rats using cystometry...
March 7, 2019: European Journal of Pharmacology
M Rieken, T R W Herrmann, C Füllhase
BACKGROUND: Benign prostatic hyperplasia (BPH) is the most common condition affecting the male lower urinary tract. Besides transurethral resection of the prostate (TURP), vaporization of the prostate and endoscopic enucleation of the prostate are available. OBJECTIVES: To provide an overview of the current status of surgical therapies for BPH. MATERIALS AND METHODS: Narrative review of the literature on the surgical treatment of BPH. RESULTS: Besides TURP, which still can be regarded as the reference technique for surgical treatment of BPH in men with a prostate volume <80 cc, greenlight laser vaporization of the prostate (GLV) and endoscopic enucleation of the prostate (EEP) are established and evidence-based alternatives...
March 7, 2019: Der Urologe. Ausg. A
Charles R Tapping, Phil Boardman
BACKGROUND: Prostate artery embolization (PAE) is safe and effective at improving lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). PURPOSE: To assess the effectiveness of PAE on allowing successful voiding in patients with obstructive BPH (>90 cc) necessitating a urethral catheter for complete urinary retention. MATERIAL AND METHODS: Ten consecutive patients with urethral catheters for obstructing BPH were included in the prospective study...
March 7, 2019: Acta Radiologica
Jung-Hyun Kim, Hong-Sang Moon, Kyu-Shik Kim, Hwan-Sik Hwang, Jae-Sook Ryu, Sung-Yul Park
Trichomoniasis is the most common curable sexually-transmitted infection. Most Trichomonas vaginalis-infected men are asymptomatic and can remain undiagnosed and untreated, and this has been thought to result in chronic persistent prostatic infection. Chronic inflammation is regarded as the major factor in the pathogenesis and progression of benign prostatic hyperplasia (BPH) and prostatic cancer (PCa). The aim of this study is to identify seropositivity to T. vaginalis in men with prostate tumors (BPH or PCa) visited to Hanyang University Hospital...
February 2019: Korean Journal of Parasitology
Bum Sik Tae, Byeong Jo Jeon, Hoon Choi, Jun Cheon, Jae Young Park, Jae Hyun Bae
PURPOSE: A recent study demonstrated that use of tamsulosin increased the risk of dementia in benign prostate hyperplasia patients. However, this study had a number of limitations. We evaluated the association between alpha-blockers and dementia in patients with benign prostate hyperplasia. METHODS: From the National Health Insurance Service database, we collected and analyzed data pertaining to alpha-blockers and dementia in the entire Korean adult population with benign prostate hyperplasia between January 2011 and December 2011...
March 6, 2019: Journal of Urology
Steven A Kaplan
No abstract text is available yet for this article.
December 2018: Journal of Urology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"